Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Brain Tumor Pathol. 2012 Oct;29(4):192-200. doi: 10.1007/s10014-012-0084-2. Epub 2012 Feb 14.
Glioblastomas, which are the most common primary intracranial tumor, are associated with the poorest survival time, which is typically 1-2 years. Age at initial diagnosis, Karnofsky performance score, and O(6)-methylguanine DNA-methyltransferase (MGMT) promoter methylation status are the most well-documented predictors of survival in patients with newly diagnosed glioblastoma. Few studies have examined prognostic factors in patients with recurrent glioblastomas. At relapse, the pathological features of glioblastomas are affected by tumor regrowth and the influence of chemoradiotherapy during the initial treatment. Morphological transformations at recurrence include quantitative changes in tumor cells, such as the presence of giant cells and gemistocytic cell formation, radiation necrosis, and vascular structural changes. Therefore, we should carefully examine pathological findings at recurrence. In this report, we analyzed MGMT promoter status, the MIB-1 index, and the pathology of tumor samples at the first (primary tumor) and second (recurrent tumor) surgeries and clarified prognostic factors in patients with recurrent cases. In the multivariate analysis, we showed that MIB-1 indexes at the time of the second surgery (p = 0.004) persisted as a significant independent prognostic factor in survival of patients with recurrent glioblastoma.
胶质母细胞瘤是最常见的原发性颅内肿瘤,其生存时间通常为 1-2 年,预后最差。发病时的年龄、卡氏功能状态评分和 O(6)-甲基鸟嘌呤 DNA-甲基转移酶(MGMT)启动子甲基化状态是新诊断胶质母细胞瘤患者生存的最有记录证明的预测因素。很少有研究检查复发性胶质母细胞瘤患者的预后因素。在复发时,胶质母细胞瘤的病理特征受到肿瘤复发性生长和初始治疗期间放化疗的影响。复发时的形态学变化包括肿瘤细胞的定量变化,如巨细胞和颗粒细胞形成、放射性坏死和血管结构变化。因此,我们应该仔细检查复发时的病理发现。在本报告中,我们分析了首次(原发性肿瘤)和第二次(复发性肿瘤)手术时的 MGMT 启动子状态、MIB-1 指数和肿瘤样本的病理学,并阐明了复发性病例患者的预后因素。在多变量分析中,我们发现第二次手术时的 MIB-1 指数(p=0.004)是复发性胶质母细胞瘤患者生存的独立预后因素。